Michael Ehlers is to quit as head of Biogen’s troubled R&D outfit, taking a role as chief executive of New York-based venture capitalist Apple Tree Partners.
European regulators have granted a fast path to market for Calliditas Therapeutics’ potential rare kidney disease drug, Nefecon, weeks after a similar decision by the FDA.
Novartis has announced positive results from trials testing its daily fixed dose treatment two-drug combination for people with uncontrolled asthma, QMF149, and its triple combination QVM14
Germany’s Evotec has announced another high-profile R&D partnership with big pharma, beginning a multi-year R&D partnership with Takeda, focusing on discovering small molecule drugs